case_images: PMC10946408_01
case_images: Image of skin lesions on August 9, 2022. (A) Front view of the patient, (B) Back view of the patient, (C) Right side view of the patient, (D) Neck view of the patient, (E) left side view of the patient.
case_images: fimmu-15-1356350-g001.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g001.jpg
case_images: f1
case_images: Upon palpation, the masses fluctuate, accompanied by tenderness and pruritus ( Figure 1 ).
case_images: CT variation diagram. (A) Patient 2022.8.8 CT image, (B) Patient 2022.10.27 CT image, (C) Patient 2023.3.29 CT image, (D) Patient 2023.6.5 CT image.
case_images: fimmu-15-1356350-g002.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g002.jpg
case_images: f2
case_images: Imaging examination reveals fluid accumulation in the abdominal and pelvic cavities, indistinct fat planes within the abdominal cavity, multiple soft tissue masses behind the peritoneum, unclear visualization of the inferior vena cava, thickening of the colonic hepatic flexure wall with luminal narrowing, indistinct mesenteric fat planes with multiple nodular opacities, and multiple soft tissue nodules in the subcutaneous tissue and muscles of the abdominal wall with local skin thickening ( Figure 2A ). Figure 2 ). Additionally, there was a significant improvement in the patient's skin lesions ( Figure 5 ). From August 9, 2022, to June 5, 2023, the patient's blood routine examination ( Figure 6A ) and liver function test results ( Figure 6B ) showed no significant abnormalities.
case_images: Pathological picture. (A) Pathological images of the patient's remnant stomach, partial jejunum, and partial resection specimen taken on April 30, 2020, (B) pathological images of the back skin lump taken on October 25, 2021, (C) pathological images of the left abdominal skin tissue taken on July 20, 2022, (D) immunohistochemical CK7 pathological images of the left abdominal skin tissue taken on July 20, 2022, (E) immunohistochemical CDX-2 pathological images of the left abdominal skin tissue taken on July 20, 2022, (F) Immunohistochemical STAB2 pathological image of left abdominal skin tissue taken on July 20, 2022, (G) Immunohistochemical CK8-18 pathological image of left abdominal skin tissue taken on July 20, 2022, (H) Immunohistochemical Villin pathological image of left abdominal skin tissue taken on July 20, 2022, (I) Immunohistochemical ki67 pathological image of left abdominal skin tissue taken on July 20, 2022.
case_images: fimmu-15-1356350-g003.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g003.jpg
case_images: f3
case_images: Immunohistochemical analysis showed that the sample was consistent with metastatic or infiltrative adenocarcinoma, with a high possibility of gastrointestinal origin ( Figures 3A-I ).
case_images: Treatment process diagram.
case_images: fimmu-15-1356350-g004.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g004.jpg
case_images: f4
case_images: Image of skin lesions on May 4, 2023. (A) Front view of the patient, (B) Back view of the patient, (C) Right side view of the patient, (D) Neck view of the patient, (E) left side view of the patient.
case_images: fimmu-15-1356350-g005.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g005.jpg
case_images: f5
case_images: Figure 2 ). Additionally, there was a significant improvement in the patient's skin lesions ( Figure 5 ). From August 9, 2022, to June 5, 2023, the patient's blood routine examination ( Figure 6A ) and liver function test results ( Figure 6B ) showed no significant abnormalities.
case_images: *:Normal value range for tumour markers, CA199(0-27U/ml), CA242(0-10U/ml), CEA(0-5.2ng/ml), AFP(0-7ng/ml). (A) Blood routine changes, (B) Changes in tumor markers, (C) Liver function change map.
case_images: fimmu-15-1356350-g006.jpg
case_images: PMC10946408_01_fimmu-15-1356350-g006.jpg
case_images: f6
case_images: Figure 2 ). Additionally, there was a significant improvement in the patient's skin lesions ( Figure 5 ). From August 9, 2022, to June 5, 2023, the patient's blood routine examination ( Figure 6A ) and liver function test results ( Figure 6B ) showed no significant abnormalities. The tumor markers exhibited a decreasing trend and remained within the normal range ( Figure 6C ).